

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>									ATTY. DOCKET NO. PC11008C			SERIAL NO. To Be Assigned					
									APPLICANT Robert F. Day, et al.								
									FILING DATE Herewith						GROUP Assigned To Be		
U.S. PATENT DOCUMENTS																	
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	US	6	2	9	1	4	9	1	9/18/01	Weber, et al.	514	357					
	US	5	1	5	3	2	1	0	10/6/92	Ainsworth	514	369					
	US	5	9	7	7	1	2	4	11/2/99	Dow	514	272					
	US	4	3	5	8	4	5	5	11/9/82	Atkinson	424	263					
	US	5	6	8	4	0	2	2	9/4/97	Shuto, et al.	514	335					
	US	5	1	3	5	9	3	2	8/4/92	Hauel, et al.	514	253					
	US	5	0	5	1	4	2	3	09/24/91	Lis et al	514	252					
FOREIGN PATENT DOCUMENTS																	
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
													YES	NO			
✓	EP	0	2	9	5	8	2	8	12/21/88	European	C07D	277/34					
✓	EP	0	5	4	3	6	6	2	9/18/96	European	C07C	217/22					
✓	EP	0	2	0	6	2	5	8	6/19/86	European	F25D	23/06					
✓	WO	9	9	6	5	8	7	7	12/23/99	International	C07D	213/80					
✓	WO	0	2	0	6	2	5	8	1/24/02	International	C07D	277/42					
✓	WO	9	9	4	5	0	0	6	10/10/99	International	C07D	413/14					
✓	WO	9	0	0	0	5	4	8	1/25/90	International	C07D	223/58					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																	
		CA 136:134753, Malamas, et al., 2002															
		CA 135:242138, Ashton, et al., 2001															
<div style="display: flex; justify-content: space-between;"> EXAMINER DATE CONSIDERED </div>																	
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with</small>																	

EXPRESS MAIL NO. 2V271824814US

INFORMATION DISCLOSURE CITATION LIST.DOT, 9/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
ROBERT F. DAY, et al.

Serial No.: Divisional of U.S. Patent
Application Serial No.
10/379,976 filed March 5,
2003.

For: β_3 ADRENERGIC RECEPTOR
AGONISTS AND USES
THEREOF

Group Art Unit: 1625

Examiner: N/A

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: January 20, 2004

Respectfully submitted,

Arlene K. Musser

Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 715-0871

EXPRESS MAIL NO. 5027182481405